ClinVar Miner

Submissions for variant NM_000497.3(CYP11B1):c.1120C>A (p.Arg374=) (rs61752786)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Integrated Genetics/Laboratory Corporation of America RCV000454869 SCV000052289 likely benign not specified 2019-09-10 criteria provided, single submitter clinical testing Variant summary: CYP11B1 c.1120C>A (p.Arg374Arg) alters a non-conserved nucleotide located close to a canonical splice site and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. 5/5 computational tools via ALAMUT predict no significant impact on normal splicing. Another tool for predicting the outcome of synonymous variants, namely Transcript-inferred Pathogenicity score (TraP, Gelfman_2017) predicts this variant to be possibly pathogenic. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 0.017 in 248518 control chromosomes in the gnomAD database, including 57 homozygotes. The observed variant frequency is approximately 8.5 fold the estimated maximal allele frequency expected for a pathogenic variant in CYP11B1 causing Congenital Adrenal Hyperplasia phenotype (0.002), strongly suggesting that the variant is benign. c.1120C>A has been reported in the literature in individuals affected with Congenital Adrenal Hyperplasia, but without strong evidence for causality (Dundar_2019). This report does not provide unequivocal conclusions about association of the variant with Congenital Adrenal Hyperplasia. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Three other clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as benign/likely benign. Based on the evidence outlined above, the variant was classified as likely benign.
Illumina Clinical Services Laboratory,Illumina RCV000029637 SCV000472330 likely benign Congenital adrenal hyperplasia 2016-06-14 criteria provided, single submitter clinical testing
Illumina Clinical Services Laboratory,Illumina RCV000397180 SCV000472331 likely benign Hyperaldosteronism, familial, type I 2016-06-14 criteria provided, single submitter clinical testing
Laboratory for Molecular Medicine, Partners HealthCare Personalized Medicine RCV000454869 SCV000538763 benign not specified 2016-03-28 criteria provided, single submitter clinical testing Variant identified in a genome or exome case(s) and assessed due to predicted null impact of the variant or pathogenic assertions in the literature or databases. Disclaimer: This variant has not undergone full assessment. The following are preliminary notes: Frequency (too high for associated disease - congenital adrenal hyperplasia)
Athena Diagnostics Inc RCV000711393 SCV000841756 benign not provided 2017-11-24 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.